Chronic lymphocytic leukaemia in COVID‐19

The patient was transferred to the intensive care unit, given 1 unit of red blood cell transfusion and placed on 10 L/min of 60% oxygen. IL‐6 is generally considered as a B‐cell growth factor, promoting tumour cell proliferation, survival, angiogenesis and immune suppression.7 However, a vast pletho...

Full description

Saved in:
Bibliographic Details
Published in:International Journal of Laboratory Hematology 2020-12, Vol.42 (6), p.e263-e265
Main Authors: Vardanyan, Robert, Arjomandi Rad, Arian, Wilson, Florence
Format: Article
Language:English
Subjects:
chronic lymphocytic leukaemia
Chronic lymphocytic leukemia
COVID-19
Letter to the Editor
Letter to the Editors
Leukemia
lymphocytosis
Citations: Items that this one cites
Items that cite this one
Online Access:Request full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The patient was transferred to the intensive care unit, given 1 unit of red blood cell transfusion and placed on 10 L/min of 60% oxygen. IL‐6 is generally considered as a B‐cell growth factor, promoting tumour cell proliferation, survival, angiogenesis and immune suppression.7 However, a vast plethora of recent studies suggest that IL‐6 may have both pro‐ and antiproliferative properties on the tumour microenvironment.8 Indeed, IL‐6 was also found to be a key player in lymphocyte activation, proliferation and survival, thus potentially supporting protective antitumour immunity.8 Nevertheless, the scale of the impact of tocilizumab on white blood cell count and in CLL patient has not been established yet with present contrasting evidence. While the use of Tocilizumab should be recognized as a cofounding factor in our case, larger trials need to assess the interaction between COVID‐19, interleukin‐6 (IL‐6) inhibition and CLL to provide optimal care for this vulnerable patient population.
ISSN:1751-5521
1751-553X
DOI:10.1111/ijlh.13307